1 BTC
=
- USD
Ultragenyx Pharmaceutical Inc.
As of May 30, 2026 at 24:05 UTC
Chart
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Market Statistics
Trading Metrics
How to Buy RARE
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy RARE
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesA class action lawsuit has been filed against Ultragenyx Pharmaceutical for allegedly providing misleading statements about setrusumab's efficacy in treating Osteogenesis Imperfecta. The company claimed the drug would reduce fracture rates, but Phase III Orbit and Cosmic studies failed to achieve statistical significance on primary endpoints. Ultragenyx stock plummeted 42.32% on December 29, 2025, following the announcement of study failures. Investors who purchased shares between August 3, 2023, and December 26, 2025, have until April 6, 2026, to apply as lead plaintiffs.
Rosen Law Firm is notifying investors in BlackRock TCP Capital Corp. (TCPC) and other companies about ongoing securities class action lawsuits. The firm is seeking a lead plaintiff by the April 6, 2026 deadline. According to the lawsuit, BlackRock TCP made materially false statements regarding investment valuations, portfolio quality, and net asset value, resulting in investor losses.
Rosen Law Firm has filed securities class action lawsuits against Ultragenyx Pharmaceutical, Kyndryl Holdings, and Vital Farms, urging investors with significant losses to secure legal counsel before upcoming deadlines. The Ultragenyx case alleges the company made misleading statements about setrusumab's effectiveness in treating Osteogenesis Imperfecta, claiming bone density increases did not correlate to reduced fracture rates as promised.
A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. alleging that the company made false and misleading statements regarding its Phase III Orbit study for setrusumab treatment of Osteogenesis Imperfecta. The complaint claims Ultragenyx failed to disclose risks associated with basing optimistic interim analysis benchmarks on Phase II results without proper placebo controls, potentially overstating the drug's efficacy. Investors who purchased securities between August 3, 2023 and December 26, 2025 may be eligible to join the class action.
Ultragenyx Pharmaceutical faces a securities fraud class action lawsuit covering the period from August 3, 2023 to December 26, 2025. The lawsuit was triggered by the company's announcement that Phase 3 studies for setrusumab failed to demonstrate statistically significant reduction in fracture rates, resulting in a 42% stock price decline from $34.19 to $19.72. Investors have until April 6, 2026 to request lead plaintiff status.